An EU private label perfume project needs a defined responsible person, qualified safety review, controlled product file, compliant manufacture, labeling and notification. This guide assigns those workstreams and distinguishes already-passed allergen transition dates from future sell-through conditions. It does not confirm any product is cleared for sale.
1. The Legal Foundation: EU Cosmetic Regulation (EC) No 1223/2009
A fragrance intended to perfume the body generally fits the cosmetic definition; confirm the actual intended use and claims. Regulation (EC) No 1223/2009 provides the applicable safety and other obligations. A home fragrance or a product presented with medicinal purposes requires its own classification review.
Identify the EU-established responsible person under the actual manufacturer/importer/distributor or designation arrangement. Written appointment and acceptance are required where the chosen arrangement calls for them. An overseas manufacturing supplier does not become the RP merely by providing documents or portal help.
2. Must‑Have Compliance Building Blocks
Before market placement, complete the applicable obligations, including the following workstreams. Their completion depends on the actual product and responsible roles:
- CPSR: Product-specific Part A information and qualified Part B assessment, with covered versions, signed conclusion and any limitations resolved.
- PIF: Maintain the statutory file, relevant evidence and animal-testing information, with lawful access and ten-year retention from last batch market placement. It is not automatic cruelty-free claim proof.
- CPNP: Submit the applicable information before placement and maintain it; notification is not approval.
- GMP: Manufacture must comply with GMP. Use applicable harmonized-standard evidence where appropriate; an ISO 22716 certificate is not the sole statutory route or proof of every product’s compliance.
3. Fragrance Allergens: What Must Be Declared
Use the current Annex III entries and applicable grouping/naming rules for fragrance allergens in the complete final formula. The relevant labeling thresholds for listed substances are generally 0.001% in leave-on and 0.01% in rinse-off products as specified by the entries; a historical “26” checklist is not sufficient to determine current artwork.
Regulation (EU) 2023/1545 is an adopted amendment, not a future plan. Its conditional transition allowed affected products compliant with the earlier rules to be placed on the market until 31 July 2026 and made available until 31 July 2028. As of the 10 October 2026 source check, the placement date has passed. Confirm eligibility and evidence for stock relying on the later availability transition; a planned new launch cannot treat 2026 as still upcoming.
How to stay ahead
- Request current fragrance/allergen data sufficient for full-formula review, including contributions from other relevant ingredients.
- Review applicable supplier IFRA conformity information for the actual mixture, intended use and standards; it does not replace legal or safety review.
- Work with a safety assessor who understands complex fragrance compositions and can pre‑screen for allergenic thresholds.
4. Labeling Essentials for EU‑Compliant Perfume
Review Article 19 for the actual bottle, outer package and any small-package exceptions. Member State language requirements apply to specified information; not every ingredient name is freely translated. The table is a review aid, not approved artwork:
| Review item | Applicability question | Illustrative placeholder |
|---|---|---|
| RP / imported origin | Correct eligible party/address and required origin? | RP ___; origin ___ |
| Nominal content | Actual fill and relevant exceptions? | 50 mL concept; no automatic ℮ eligibility |
| Durability | Minimum-durability date or PAO where applicable, including exceptions? | Assessor-supported indication ___ |
| Batch | Traceable finished-batch reference? | Lot ___ |
| Ingredients/allergens | Final formula and current naming/transition review? | Ingredients: final approved list ___ |
| Function/precautions | Function unless obvious; applicable safe-use wording? | Approved description/warnings ___ |
5. Working with a Private Label Manufacturer: Your Compliance Checklist
Confirm exactly what the supplier can provide, under what access terms, and who performs qualified review. Discuss the following records without assuming they are a universal certificate bundle or included service:
- Material/hazard information: Obtain relevant records and SDS where applicable; do not require an identical SDS package for all raw materials and finished cosmetics without scope review.
- Fragrance conformity: Confirm actual supplier document, mixture identity, use category and applicable standards/version.
- Full qualitative and quantitative formula (to be shared confidentially with your safety assessor).
- Manufacturing/GMP: Request the method and compliance statement with appropriate supporting records; verify any claimed certificate scope separately.
- Technical evidence: Agree formula/package-specific stability and microbiological controls with the qualified reviewer, including any testing or justified approach.
- Clarity on whether the manufacturer can act as your Responsible Person or if you need to appoint one separately.
6. Conditional Project Schedule
Illustrative dependency plan: once the actual formula, components, intended use and market brief are identified, assign dates to each gate below. The previous blanket eight-to-twelve-week estimate is not a verified delivery commitment; missing studies or revisions can change the schedule.
- Brief and inputs: Identify formula/package versions and missing data; owner/date ___.
- Qualified assessment/file: Complete required evidence and report/file review; owner/date ___.
- Artwork: Approve actual destinations, applicable transition and final label version; owner/date ___.
- Notification: Complete applicable submission and retain version record; owner/date ___.
- Manufacture/release: Confirm process, batch evidence and all release conditions; owner/date ___.
Fill in start, completion, reviewer and unresolved items for each gate. Parallel work is possible only where its inputs and risk controls permit it. Notification alone does not replace safety, label, manufacturing or other market-placement obligations.
Responsibility and sign-off matrix
| Party | Work to assign | Evidence / decision |
|---|---|---|
| Manufacturer | Controlled formula/material/process/package inputs and contracted studies | Document versions and actual results; no assumed RP role |
| Brand | Markets, intended users/claims, packaging choices and commercial brief | Approved brief and artwork inputs |
| Qualified safety assessor | Assess actual product using adequate information | Signed CPSR scope, limitations and updates |
| Responsible person | Ensure applicable duties, PIF access and notification | Reviewed file, current records and market-placement decision |
Sources checked on 10 October 2026: current EU Cosmetics Regulation, Regulation (EU) 2023/1545 and its conditional transitions and IFRA guidance. A qualified compliance reviewer still needs to confirm the actual product, stock-transition evidence and destination artwork.
Frequently Asked Questions
Do I personally need to register my perfume with the EU?
The applicable cosmetic route uses CPNP notification, performed by or for the responsible person under the required authority. A successful submission is not product approval or an automatic right to sell across all markets. Complete the other obligations and destination-specific label review.
Is an IFRA certificate mandatory by law?
Supplier IFRA conformity information may support the qualified assessment, but is not itself a legal market permit or a substitute for the finished-product assessment. Confirm its actual mixture, intended use and applicable standards rather than asserting every assessor requires the same named document.
Can I use the same label for all EU countries?
Assess the proposed label against the actual destination countries, required information, language rules and physical-package constraints. A multilingual design or sticker must still be compliant and legible; one label is not automatically acceptable everywhere.
What if my fragrance house only gives me the 26 allergens list?
Request the data needed to evaluate the complete formula against current Annex III and the applicable transition. A limited legacy list is not enough to conclude the current label is correct. Document gaps and resolve them before approval; do not predict reformulation without assessing the actual composition.
Does an alcohol‑based perfume need a preservative efficacy test?
The qualified assessor should determine the microbiological evidence or justified approach for the actual formula and package. Alcohol percentage alone does not establish a universal challenge-test exemption or demonstrate in-use safety. Retain the reasoning and applicable evidence.
LAEYO does not currently provide CPSR safety assessments or complete PIF preparation. Confirm any other manufacturing and documentation services in the quotation. This guide does not establish an in-house regulatory team or completed label review. Assign qualified reviewers and secure necessary data access.
To discuss an EU fragrance project and the evidence needed, Request a Quote. Arrange any required CPSR assessment and complete PIF preparation separately, and confirm the scope, costs and schedule with the chosen providers.